The inhibition of autocrine CXCL8 signaling has been shown to sensitize PTEN-deficient or p53-mutant cancer cells to DNA-damaging agents, anti-metabolites or androgen receptor-targeting strategies [50,78,79,81], while the anti-angiogenic activity of the CXCL8-targeting strategies have been shown to augment anti-angiogenic responses elicited by docetaxel in ovarian and prostate cancer models [126,181]. Here, CXCL8 is linked to prostate cancer.